QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Newly launched resources for RWD sources and how they can be used for non-interventional post-authorization studies!
Two renewed electronic catalogues of real-world data (RWD) sources and studies to enhance data discoverability have recently been launched by EMA and Heads of Human Medicines.
👉 The Catalogue of RWD Sources replaces the ENCePP Resources Database, offering a centralised repository for RWD sources and is a great starting point for someone interested in RWD to identify and use such data to investigate the use, safety, and effectiveness of medicines.
Yet, […]
Welcome Raphaela!
Welcome to the team Raphaela Mayerhofer, PhD.
Raphaela joins the RWE team in Stockholm following a career at Karolinska Institutet, Södertörn University, and the Medizinische Universität Graz, amongst others.
Alongside her academic career Raphaela has also been working as a scientific writer for a variety of clients.
“I’m excited to join the team at Quantify, leveraging the potential of Scandinavian health data to better […]
While we are all waiting for the delayed implementing acts for the EU HTA and the Joint Clinical Assessment (JCA), let´s summarize what we know so far about JCA
· What is it?
JCA is a streamlined EU-level process that evaluates the relative effectiveness and safety of new treatments compared to a range of alternative treatments. It considers a range of relevant treatments across EU member states. The resulting JCA report informs national HTA processes.
· Aim:
The JCA aims to eliminate inequality across European countries, reduce redundancy in the parallel national HTA processes, increase quality of […]
Welcome Ana!
Quantify is proud to introduce Ana Buzatu, who will support our Model, Access, and Strategy team in Stockholm as a Junior Research Analyst.
Ana is a pharmacist currently pursuing a master’s degree in Health economics, Policy and Management at Karolinska Institutet. Before joining Quantify, she worked in the pharmaceutical and diagnostics industry, bringing an integrated perspective on access and policy.
“I am excited to be part of […]